• Auxilium Pharmaceuticals Inc., of Malvern, Pa., reported net revenue of $61.8 million for the quarter ending Dec. 31, 2010, and full-year 2010 net revenues of $211.4 million from sales of Xiaflex (collagenase clostridium histolyticum) for the treatment of adult Dupuytren's contracture patients with a palpable cord and Testim 1 percent, a testosterone gel, for the topical treatment of hypogonadism. Worldwide revenues for Xiaflex, which was launched in March 2010, were $18.4 million and $14.1 million in the U.S. Worldwide revenues for Testim were $193 million for the year, up 20 percent over 2009, with U.S. revenues up 25 percent over the prior year to $190 million. Net loss for the quarter was $16.4 million and net loss for the full year was $51.2 million. The company had $128.2 million in cash.